Prima Secures Japanese Patent Grant for IMP731 Antibody
September 08 2017 - 1:25AM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”)
announces the grant of Japanese patent no. 6177735 entitled
“Cytotoxic anti-LAG-3 monoclonal antibody and its use in the
treatment or prevention of organ transplant rejection and
autoimmune disease” by the Japanese Patent Office.
The patent was filed as a divisional application and is directed
to Prima’s IMP731 antibody that was originally developed by Immutep
SA, now a wholly owned subsidiary of Prima. The granted
claims provide broad protection for the antibody and also use of
the antibody in the manufacture of a medicament for treating or
preventing organ transplant rejection or treating an autoimmune
disease. The patent expiry date is 30 April 2028.
Rights for the development of the IMP731 antibody were granted
in December 2010 to GSK who have commenced first-in-human clinical
trials of a proprietary antibody (GSK2831781) derived from
IMP731.
About IMP731 and GSK2831781IMP731 and
GSK2831781 are designed to specifically deplete potentially
pathogenic, recently activated, LAG-3 expressing T cells which are
enriched at the disease site in T-cell driven immuno‐inflammatory
disorders and should spare other T-cells which may be necessary for
other functions.
Under the terms of the 2010 agreement between Immutep and GSK,
GSK has responsibility for all development costs for GSK2831781.
Under the agreement, Prima is entitled to receive payments and
milestones totalling up to £64 million and single-digit, tiered
royalties if all objectives are achieved.
A Phase 1, first-in-human clinical study of GSK2831781 for the
treatment of autoimmune diseases has commenced and further
information may be obtained at
https://clinicaltrials.gov/ct2/show/NCT02195349.
About Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
Australian Investors/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Sep 2023 to Sep 2024